Summary: Antisense oligonucleotide therapeutics have been in development for almost 25 years without a single USFDA approved product in cancer. The reasons, for this stem, in part, from a deep lack of understanding of how to deliver these molecules to cancer cells in vivo. ________________________________________________________________ In this issue of Clinical Cancer Research, Hong, et al (1) report on the safety and tolerability of LY2275796, a second generation antisense oligonucleotide (ASO) targeted to the eukaryotic translational initiation factor eIF-4E mRNA, a gene that has been reported to play a role in tumor initiation.
phosphorothioate ASOs (those without any additional chemical modifications) have been believed to be exonuclease resistant, they are probably insufficiently so for in vivo gene silencing. (The use of 2'-methoxyethoxyoligoribonucleotide gapmers, as done by Hong, et al (1) , both greatly enhances nuclease resistance, and increases T m ). The combination of insufficient in vivo nuclease resistance and the diminution of T m after phosphorothioate substitution have probably done much to vitiate the efficacy of phosphorothioate ASOs in earlier clinical trials in cancer. These problems were not apparent in experiments performed in tissue culture, because the ASOs were delivered into cells by lipofection, which provided extremely high nuclear concentrations. Further, data from in vivo experiments was often interpreted as resulting from antisense gene silencing, when it fact it resulted from CpG sequence motifs in the phosphorothioate ASO binding to TLR9 receptors on mouse plasmacytoid dendritic cells, with the resulting "cytokine storm" leading to inhibition of tumor growth (6) .
In the ultra-complex world of phosphorothioate ASOs, Oblimersen is an outlier, as its T m with its target Bcl-2 mRNA (codons 1-6), for unclear reasons, is significantly higher than predicted. However, Oblimersen contains two CpG motifs and is highly immunostimulatory (6) . While earlier work suggested that Bcl-2 was an important target in melanoma, later work challenged this idea (7), and it is difficult to understand how silencing of this gene can meaningfully chemosensitize a virulent tumor with such extensive redundant signaling pathways (8) . Nevertheless a small phase II trial performed in combination with DTIC was successful (9) , and thus was launched the GM301 trial (4). This non-blinded, randomized, trial in 775 patients compared Oblimersen + DTIC vs. DTIC alone. Patients were also pre-stratified by baseline LDH. A continuous improvement in overall survival (OS) was observed in the patients receiving Oblimersen as a function of baseline LDH. , Patients whose LDH was less than or equal to 0.8 times the upper limit of normal (ULN) showed the greatest benefit in OS, and those with LDH at >1.1 x ULN demonstrated no difference in OS (10) . Based on these results, a randomized, phase 3 trial of Oblimersen + DTIC vs. DTIC alone was performed in 300 patients with LDH < 0.8 x ULN (GM307). Here, however, no difference in OS was observed. Thus ended clinical trials of Oblimersen, which had also failed in myeloma and whose development in CLL was also halted.
Why was the data in the earlier trial not reproduced? The probable reason was that the GM301 trial was not blinded, unlike GM307, and patients received an average of 5 cycles of DTIC (a minimally active anti-melanoma drug) in GM307 (vs. 3.2 cycles in the GM301 study). This difference was sufficient to eliminate the observed increase in OS in the low LDH population in GM301
But would have a successful GM307 constituted that elusive in vivo proof of principle? The answer in our opinion is no. Even ignoring the issue of whether Bcl-2 is a target in melanoma, the question of whether sufficient ASO enters melanoma cells, or any other cancer cell clinically to reproducibly and robustly silence any target has never been answered. This contention is also true of LY2275796 in this trial, which appears to silence its target and down-regulate housekeeping genes with similar potency and must thus be suspected of accomplishing both here non-specifically.
Despite huge expenditure on a vast array of delivery strategies, carrier molecules, etc., all of which suffer from cost issues, toxicity, poor delivery to tumors, or a combination, the foremost technologic hurdle blocking clinical progress for therapeutic ASOs (antisense and siRNA) in cancer is delivery. ASOs administered to patients in phase I and II trials can be found at high concentration in liver, kidney and small intestine, but whether sufficient concentrations for gene silencing are found in tumors, and critically, intracellularly, is unknown. Further, optimal concentrations may differ dramatically depending on tumor type, ASO chemistry, route of administration, and dose schedule, none of which are We do know that for some newer modified ASO gap-mers that produce nuclease resistance and increased T m , (e.g., those containing 3' and 5' locked nucleic acids), no carriers are required, at least in vitro, for gene silencing (11) . However, it is unclear if silencing can be produced in human tumors with these ASOs, despite some unpublished successes in human tumor xenograft models in mice. This is the road not taken in oligonucleotide therapeutics for cancer: In the search for the most rapid path to the market, the difficult, time-consuming and costly work of meticulously studying the delivery process has never been undertaken. And for this lack of knowledge, the field of oligonucleotide therapeutics, despite the occasional glimmer of hope as described by Hong, et al., (1) continues to pay the price in its lack of clinical activity in cancer. 
